Ostezolen - Pharmacology: Inhibition of osteoclastic bone resorption.
Treatment and prevention of osteoporosis in postmenopausal women; treatment to increase bone mass in men with osteoporosis; treatment and prevention of glucocorticoid-induced osteoporosis in men and women; treatment of Paget disease of bone in men and women.
Treatment of hypercalcemia of malignancy; treatment of patients with multiple myeloma and bone metastases from solid tumors in conjunction with standard antineoplastic therapy.
Ostezolen is used to treat bone diseases that occur together with certain types of cancers. Certain types of cancers cause the calcium in your bones to leak out into the bloodstream. This can cause problems such as weak bones, fractures, bone pain and metabolic disturbances. Ostezolen helps to prevent calcium from leaking out of your bones. It helps to strengthen your bones and reduce the chances of getting fractures and bone pain. It also helps to lower the level of calcium in the bloodstream -- this helps to prevent metabolic disturbances. Ostezolen is also used to treat Paget's disease, a painful bone condition which can cause abnormal bone growth and deformity. Ostezolen helps to regulate the growth of bone in Paget's disease. Ostezolen can also be used to strengthen thin and weak bones in people who have or are at risk of osteoporosis. It helps to stop the loss of bone and also helps to increase bone mass.
Intravenous Hypercalcaemia of malignancy
Adult: 4 mg as a single dose by infusion over at least 15 minutes. Retreatment in patients who relapse or who are refractory to initial treatment: 4 mg as an infusion over at least 15 minutes, after at least 1 wk from initial dose. Renal impairment: Serum creatinine >400 micromol/L: Avoid. Intravenous Bone metastases associated with solid tumours
Adult: 4 mg infusion over at least 15 minutes every 3-4 wk, in conjunction with 500 mg calcium and 400 IU vitamin D oral supplement. CrCl (ml/min) Dosage Recommendation 50-60 3.5 mg every 3-4 wk 40-49 3.3 mg every 3-4 wk 30-39 3 mg every 3-4 wk <30 Not recommended. Intravenous Osteolytic lesions associated with multiple myeloma
Adult: 4 mg infusion over at least 15 minutes every 3-4 wk, in conjunction with 500 mg calcium and 400 IU vitamin D oral supplement. CrCl (ml/min) Dosage Recommendation 50-60 3.5 mg every 3-4 wk 40-49 3.3 mg every 3-4 wk 30-39 3 mg every 3-4 wk <30 Not recommended. Intravenous Paget's disease of bone
Adult: Single 5 mg IV infusion over 15 minutes, in conjunction with 1500 mg elemental calcium daily in divided doses and 800 IU vitamin D daily, especially in the 2 wk following Ostezolen admin. CrCl (ml/min) Dosage Recommendation <40 Not recommended. Intravenous Osteoporosis in postmenopausal women
Adult: Single 5 mg IV infusion over at least 15 minutes, once a year. CrCl (ml/min) Dosage Recommendation <40 Not recommended. Reconstitution: Dilute the required amount in 100 ml of 0.9% sodium chloride or 5% dextrose. Incompatibility: Incompatible with calcium containing solutions (e.g. lactated Ringer's solution) and other divalent cation containing solutions.
Adult: IV Hypercalcaemia of malignancy 4 mg as a single dose infusion. May repeat 1 wk later if needed. Advanced bone malignancies 4 mg infusion 3-4 wkly. Paget's disease of bone 5 mg as a single dose infusion. Postmenopausal osteoporosis 5 mg as a single dose infusion, once yrly.